文献速递血栓与止血

肝素诱导的血小板减少症中血小板因子4/肝素抗体的全基因组关联研究

Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.
PubMed 文献 · Blood Adv · 2022-01-01

该研究对欧洲血统且临床怀疑肝素诱导的血小板减少症(HIT)的患者进行全基因组关联研究(GWAS),发现队列n=4237、复制队列n=807,检测抗PF4/肝素抗体水平。未发现达到全基因组显著性的变异;提示遗传变异并非肝素治疗患者抗体反应变异的主要驱动因素。

要点

  • 发现队列中无变异达到全基因组显著性水平(α=5×10⁻⁸)。
  • 两个队列中排名最前的变异均为rs1555175145。
  • 三个基因集在发现与复制队列中均达到FDR校正显著性(q<0.05)。

核心结论

  • 结果表明,基因组变异与抗PF4/肝素抗体水平无显著关联。
  • 基于识别中等频率和效应量变异的把握度,该证据提示遗传变异并非欧洲血统肝素治疗患者抗体反应变异的主要驱动因素。

研究设计与样本

  • 采用全基因组关联研究(GWAS)方法,对通过多克隆酶联免疫吸附试验测定的抗PF4/肝素抗体水平进行分析。
  • 发现队列n=4237,复制队列n=807,均为欧洲血统且临床怀疑HIT的患者,病例经功能试验确认。
  • 全基因组显著性定义为α=5×10⁻⁸。

主要发现

  • 发现队列中无变异达到全基因组显著性水平(α=5×10⁻⁸)。
  • 二次GWAS分析中,发现队列以α=1×10⁻⁴识别提示性关联变异;两个队列中排名最前的变异均为rs1555175145(发现队列β=-0.112[0.018],P=2.50×10⁻⁵;复制队列β=-0.104[0.051],P=.041)。
  • 基因集富集分析中,3个基因集在发现与复制队列中均达到FDR校正显著性(q<0.05):「白细胞跨内皮迁移」、「先天免疫反应」和「裂解酶活性」。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin, a widely used anticoagulant, carries the risk of an antibody-mediated adverse drug reaction, heparin-induced thrombocytopenia (HIT). A subset of heparin-treated patients produces detectable levels of antibodies against complexes of heparin bound to circulating platelet factor 4 (PF4). Using a genome-wide association study (GWAS) approach, we aimed to identify genetic variants associated with anti-PF4/heparin antibodies that account for the variable antibody response seen in HIT. We performed a GWAS on anti-PF4/heparin antibody levels determined via polyclonal enzyme-linked immunosorbent assays. Our discovery cohort (n = 4237) and replication cohort (n = 807) constituted patients with European ancestry and clinical suspicion of HIT, with cases confirmed via functional assay. Genome-wide significance was considered at α = 5 × 10-8. No variants were significantly associated with anti-PF4/heparin antibody levels in the discovery cohort at a genome-wide significant level. Secondary GWAS analyses included the identification of variants with suggestive associations in the discovery cohort (α = 1 × 10-4). The top variant in both cohorts was rs1555175145 (discovery β = -0.112 [0.018], P = 2.50 × 10-5; replication β = -0.104 [0.051], P = .041). In gene set enrichment analysis, 3 gene sets reached false discovery rate-adjusted significance (q < 0.05) in both discovery and replication cohorts: "Leukocyte Transendothelial Migration," "Innate Immune Response," and "Lyase Activity." Our results indicate that genomic variation is not significantly associated with anti-PF4/heparin antibody levels. Given our power to identify variants with moderate frequencies and effect sizes, this evidence suggests genetic variation is not a primary driver of variable antibody response in heparin-treated patients with European ancestry.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Giles JB, Steiner HE, Rollin J, et al. Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Adv. 2022. PMID: 35533259. doi:10.1182/bloodadvances.2022007673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。